Candel Therapeutics, INC Form 4 insider transactions

Mark E. Sims, Chief Commercial Officer of Candel Therapeutics, Inc., was granted stock options for 285,000 shares.

Candel Therapeutics Chief Scientific Officer Francesca Barone sold 23,447 shares of common stock for approximately $10.06 per share, pursuant to a 10b5-1 trading plan.

Candel Therapeutics Chief Technology Officer, Seshu Tyagarajan, reported the sale of 7,000 common shares for approximately $70,140 under a pre-established 10b5-1 trading plan.

Candel Therapeutics Director Paul B. Manning acquired stock options valued at $10.30 per share, with 2,199 options granted on June 30, 2026, in lieu of cash payments.

Candel Therapeutics Director Joseph C. Papa acquired 1,331 shares of common stock through a stock option exercise, as detailed in a recent SEC Form 4 filing.

Nicoletta Loggia, a Director at Candel Therapeutics, Inc., acquired stock options on June 30, 2026, as part of a compensation arrangement.

Maha Radhakrishnan, a Director at Candel Therapeutics, Inc., acquired 32,000 stock options with an exercise price of $9.08.

Nicoletta Loggia, a director at Candel Therapeutics, Inc., acquired 32,000 stock options with an exercise price of $9.08.

Candel Therapeutics Director Joseph C. Papa acquired 32,000 stock options with an exercise price of $9.08, vesting under specific conditions.

Candel Therapeutics Director Edward J. Benz Jr. acquired 32,000 stock options with an exercise price of $9.08, vesting over time and subject to continued board service.

Candel Therapeutics Director Christopher Martell acquired 32,000 stock options with an exercise price of $9.08, vesting over time.

Gary J. Nabel, a Director at Candel Therapeutics, Inc., acquired 32,000 stock options with an exercise price of $9.08.

Candel Therapeutics Director Diem Nguyen acquired 32,000 stock options with an exercise price of $9.08.

Candel Therapeutics Director Paul B. Manning acquired 32,000 stock options with an exercise price of $9.08, vesting under specific conditions.

Candel Therapeutics Director Paul B. Manning acquired stock options valued at $4.90 per share, with 4,618 options granted in lieu of cash payments.

Candel Therapeutics Director Joseph C. Papa acquired stock options valued at $4.90 per share on March 31, 2026, as part of a compensation arrangement.

Nicoletta Loggia, a Director at Candel Therapeutics, Inc., acquired stock options on March 31, 2026, as part of a compensation arrangement.

Candel Therapeutics Director Paul B. Manning plans to acquire 550,458 shares of common stock at $5.45 per share under a pre-arranged 10b5-1 plan.

Candel Therapeutics' Chief Technology Officer, Seshu Tyagarajan, was granted 154,000 stock options with a $6.01 exercise price, vesting over four years.

Candel Therapeutics' Chief Medical Officer, William Garrett Nichols, was granted 136,500 stock options with an exercise price of $6.01, vesting over four years.

Candel Therapeutics' Chief Financial Officer, Charles Schoch, was granted 232,000 stock options with an exercise price of $6.01, vesting over four years.

Candel Therapeutics, Inc. CEO Paul Peter Tak was granted 629,000 stock options with an exercise price of $6.01, vesting over 48 months.

Candel Therapeutics' Chief Scientific Officer, Francesca Barone, was granted 232,000 stock options with an exercise price of $6.01, vesting over four years.

Candel Therapeutics Chief Medical Officer William Garrett Nichols sold 937 shares of common stock at $6.98 per share, following the exercise of options, as part of a pre-established 10b5-1 trading plan.

Candel Therapeutics' Chief Medical Officer, William Garrett Nichols, executed a pre-planned transaction involving the exercise of stock options and the subsequent sale of common stock on June 30, 2025, under a Rule 10b5-1 trading plan.

Candel Therapeutics, Inc.'s Chief Technology Officer, Seshu Tyagarajan, acquired 5,353 shares of common stock for approximately $25,000 through a registered direct offering.

Candel Therapeutics, Inc. CEO Paul Peter Tak acquired 42,826 shares of common stock at $4.67 per share through a registered direct offering, increasing his beneficial ownership to 268,566 shares.

Paul B. Manning, a Director and 10% owner of Candel Therapeutics, Inc., acquired 1,070,663 shares of common stock at $4.67 per share in a registered direct offering.

Candel Therapeutics, Inc. Director and 10% owner Christopher Martell acquired 111,349 shares of common stock at $4.67 per share through a registered direct offering.

Candel Therapeutics, Inc.'s Chief Financial Officer, Charles Schoch, acquired 5,353 shares of common stock at $4.67 per share through a registered direct offering.